Return
Dysbiosis-associated bile acids slam the brakes on immune checkpoint therapy
C
J
DOI:10.1016/j.ccell.2026.06.013.png)
Abstract
En 中文
Antibiotics compromise the efficacy of immune checkpoint inhibition (ICI) therapy in cancer, but the underlying mechanism remains unclear. In this issue of Cancer Cell, Mallard de La Varende et al. identify dysbiosis-associated tauro-conjugated bile acids as drivers of ICI non-response and γ-glutamyl transferase (γGT) as a predictive biomarker.
Journal
IF:
44.5
Papers:
413
Citations:
5.6W
